Assessment

1. Most likely cause: linagliptin (DPP-4 inhibitor)

• DPP-4 inhibitors (linagliptin, sitagliptin, saxagliptin, vildagliptin) carry a class-wide regulatory warning for acute pancreatitis, based on post-marketing reports and some signal in linagliptin's own clinical development data (MHRA Drug Safety Update; FDA labeling).
• Mechanistically this is usually a hypersensitivity-type, dose-independent reaction, typically occurring 4-8 weeks after starting the drug, and recurring on rechallenge - Sleisenger & Fordtran's Gastrointestinal and Liver Disease, and Harrison's Principles of Internal Medicine both list DPP-4 inhibitors under drug-induced/uncommon causes of pancreatitis with this pattern.
• If linagliptin was continued or restarted after the first episode, a second attack shortly after is exactly the "rechallenge" pattern textbooks describe as the strongest evidence for drug causality.
• Standard guidance (FDA label, MHRA alert): once pancreatitis occurs on a DPP-4 inhibitor, stop it and do not rechallenge - switch to another antidiabetic class.

• Metformin - very rarely implicated, low suspicion, generally safe to continue.
• Empagliflozin (SGLT2i) - not an established cause of pancreatitis; can be continued (also avoids euglycemic DKA risk if she's eating poorly - watch for that if she becomes ketotic during this illness).
• Losartan - occasional isolated case reports only, weak evidence.
• Escitalopram / haloperidol - isolated case reports exist for SSRIs and antipsychotics, but far weaker and less consistent latency than DPP-4 inhibitors; no strong reason to stop unless everything else is negative.

2. Immediate management of this acute episode

• Admit and manage as acute pancreatitis: IV isotonic crystalloid (goal-directed, avoid aggressive over-resuscitation), analgesia, antiemetics, early oral/enteral feeding as tolerated (no need for prolonged NPO in mild interstitial disease).
• Risk-stratify with SIRS criteria/BISAP score in the first 24-48h; if she doesn't improve clinically by 48-72h, get a contrast-enhanced CT abdomen (better than USG for detecting necrosis, ductal disease, or a mass/IPMN missed on ultrasound).
• Stop linagliptin now, permanently, and do not rechallenge.
• Send/repeat: fasting triglycerides, serum calcium (+ PTH if elevated), LFTs, and if not already done, IgG4 (to screen for autoimmune pancreatitis, since this is recurrent and etiology-negative so far).

3. Diabetes regimen going forward

• Continue metformin if renal function and GI tolerance allow.
• Continue empagliflozin (no pancreatitis association) - just counsel on adequate hydration/carb intake to avoid euglycemic ketoacidosis during acute illness.
• Avoid substituting with a GLP-1 receptor agonist for now - these carry their own (weaker but real) pancreatitis signal, and in a patient with two recent attacks it's prudent to avoid the whole incretin-based drug class until a firm alternative etiology is found.
• If glycemic control needs a third agent, consider a sulfonylurea (cautiously, given hypoglycemia risk) or basal insulin rather than an incretin-based drug.

4. Since this is her second attack with a "clean" workup so far, don't stop at "idiopathic" - go further

• MRCP or endoscopic ultrasound (EUS) - to look for microlithiasis, sludge, pancreas divisum, or a small ampullary/pancreatic lesion (relevant at age 52).
• Confirm triglycerides and calcium are normal (not just historically, but at presentation).
• Ask specifically about smoking (independent risk factor for pancreatitis and progression to chronic disease) and any family history of pancreatitis/pancreatic disease.

5. Longer-term follow-up

• Because she's had two attacks in close succession, monitor for evolution toward chronic pancreatitis: watch for steatorrhea/weight loss (check fecal elastase if symptoms arise) and worsening glycemic control (possible pancreatogenic component).
• Reassess her anxiety medications (escitalopram, haloperidol 0.25 mg) with psychiatry only if a third episode occurs after excluding other causes - they are low-probability culprits and shouldn't be stopped reflexively.
• Document the linagliptin-associated pancreatitis clearly in her chart/allergy list so no DPP-4 inhibitor is prescribed to her again.